| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries[J]. CA Cancer J Clin，2021, 71(3):209-249.
|
| [2] |
Zhang Q, Lou Y, Yang J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J]. Gut, 2019, 68(11): 2019-2031.
|
| [3] |
Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy[J]. Nat Immunol, 2016, 17(9):1025-1036.
|
| [4] |
Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells[J]. Nat Immunol, 2008, 9(5):503-510.
|
| [5] |
Böttcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control[J]. Cell, 2018, 172(5):1022-1037, e14.
|
| [6] |
Marquardt N, Béziat V, Nyström S, et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells[J]. J Immunol, 2015, 194(6):2467-2471.
|
| [7] |
Mikulak J, Bruni E, Oriolo F, et al. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology[J]. Front Immunol, 2019(10):946.
|
| [8] |
Lee HA, Goh HG, Lee YS, et al. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma[J]. BMC Gastroenterol, 2021, 21(1):258.
|
| [9] |
Han C, Jiang Y, Wang Z, et al. Natural killer cells involved in tumour immune escape of hepatocellular carcinomar[J]. Int Immunopharmacol, 2019(73):10-16.
|
| [10] |
Han B, Mao FY, Zhao YL, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer[J]. J Immunol Res, 2018: 6248590.
|
| [11] |
Xu D, Han Q, Hou Z, et al. miR-146a negatively regulates NK cell functions via STAT1 signaling[J].Cell Mol Immunol, 2017, 14(8): 712-720.
|
| [12] |
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells[J]. Nat Immunol, 2017, 18(9):1004-1015.
|
| [13] |
Chew V, Lai L, Pan L, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J].Proc Natl Acad Sci U S A, 2017, 114(29):E5900-5909.
|
| [14] |
Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation[J]. Semin Cancer Biol, 2017(43):74-89.
|
| [15] |
Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells[J]. Cell Metab, 2016, 24(5):657-671.
|
| [16] |
Lacroix R, Rozeman EA, Kreutz M, et al. Targeting tumor-associated acidity in cancer immunotherapy[J]. Cancer Immunol Immunother, 2018, 67(9):1331-1348.
|
| [17] |
Zheng X, Qian Y, Fu B, et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance[J]. Nat Immunol, 2019, 20(12):1656-1667.
|
| [18] |
Cui C, Fu K, Yang L, et al. Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):229.
|
| [19] |
Arvanitakis K, Koletsa T, Mitroulis I, et al. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy[J]. Cancers, 2022, 14(1):226.
|
| [20] |
Zheng Y, Chen Z, Han Y, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment[J].Nat Commun, 2020, 11(1):6268.
|
| [21] |
Wang S, Wu Q, Chen T, et al. Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model[J]. J Hepatol, 2022, 77(2):467-478.
|
| [22] |
沈锋, 林间, 王海波. 肝细胞癌免疫微环境研究进展及未来方向[J]. 中国实用外科杂志, 2021, 41(1): 42-47.
|
| [23] |
Berger L, Shamai Y, Skorecki KL, et al. Tumor specific recruitment and reprogramming of mesenchymal stem cells in tumorigenesis[J]. Stem Cells, 2016, 34(4):1011-1026.
|
| [24] |
Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation[J]. Blood, 2006, 107(4):1484-1490.
|
| [25] |
李华杰, 王福生, 施明. 间充质干细胞治疗与自然杀伤细胞的相互作用[J]. 中国免疫学杂志, 2020, 36(10):1262-1265.
|
| [26] |
Rennert C, Tauber C, Fehrenbach P, et al. Adaptive subsets limit the anti-tumoral NK-cell activity in hepatocellular carcinoma[J]. Cells, 2021, 10(6):1369.
|
| [27] |
Cuff AO, Sillito F, Dertschnig S, et al. The obese liver environment mediates conversion of NK cells to a less cytotoxic ILC1-like phenotype[J]. Front Immunol, 2019(10):2180.
|
| [28] |
Barry AE, Baldeosingh R, Lamm R, et al. Hepatic stellate cells and hepatocarcinogenesis[J]. Front Cell Dev Biol, 2020(8):709.
|
| [29] |
Lin M, Liang S, Wang X, et al. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer[J]. Oncotarget, 2017, 8(47):81967-81977.
|
| [30] |
陈雅雯, 田志刚, 彭慧. 肝脏NK细胞亚群的异质性[J]. 中国科学:生命科学, 2022(52):1-12.
|
| [31] |
Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy[J]. Acta Pharmacol Sin, 2018, 39(2):167-176.
|
| [32] |
Kalathil SG, Thanavala Y. Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches[J]. Cells, 2021, 10(6):1332.
|
| [33] |
Yu M, Luo H, Fan M, et al. Development of GPC3-Specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma[J]. Mol Ther, 2018, 26(2):366-378.
|
| [34] |
Liu Y, Cheng Y, Xu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers[J]. Oncogene, 2017, 36(44):6143-6153.
|
| [35] |
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J].中华外科杂志, 2022, 60(4):273-309.
|
| [36] |
van Hall T, André P, Horowitz A, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A[J]. J Immunother Cancer, 2019, 7(1):263.
|
| [37] |
Hanna GJ, O'neill A, Shin KY, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2022, 28(3):468-478.
|
| [38] |
Yalniz FF, Daver N, Rezvani K, et al. A pilot trial of lirilumab with or without azacitidine for patients with myelodysplastic syndrome[J].Clin Lymphoma Myeloma Leuk, 2018, 18(10):658-663, e2.
|